rs12102416 - WFDC1 - ATP2C2
Magnitude 2.2 · 1 study on file
Reported associations
-
Genome-wide association study of liver enzyme elevation in an extended cohort of rheumatoid arthritis patients starting low-dose methotrexate. - Pharmacogenomics (2022) · Cavalli M, Eriksson N, Sundbaum JK, Wallenberg M, Kohnke H, Baecklund E, Hallberg P, Wadelius M · PubMed 36070248
A follow-up genome-wide association study (GWAS) in an extended cohort of rheumatoid arthritis (RA) patients starting low-dose methotrexate (MTX) treatment was performed to identify further genetic variants associated with alanine aminotransferase (ALT) elevation. A GWAS was performed on 346 RA patients. Two outcomes within the first 6 months of MTX treatment were assessed: ALT >1.5-times the upper level of normal (ULN) and maximum level of ALT. (rs72783407) was significantly associated with maximum level of ALT (p = 2.58 × 10 ) and (rs60427389) was tentatively associated with ALT >1.5 × ULN. Associations with SNPs in genes related to male fertility ( ) and inflammatory processes ( ) were identified.
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Bloodwork
-
Alanine aminotransferase (ALT) with methotrexate therapy Moderate
ATP2C2 variant rs12102416 associated with elevated ALT levels after methotrexate initiation in rheumatoid arthritis
Request baseline ALT before starting methotrexate and monitor during therapy